Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- PHVS
- Price
- 26.61
- Stock movement up
- +0.16 (0.60%)
- Company name
- Pharvaris BV
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.73B
- Ent value
- 1.43B
- Price/Sales
- -
- Price/Book
- 5.54
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 56.70%
- 1 year return (CAGR)
- 53.20%
- 3 year return (CAGR)
- 41.06%
- 5 year return (CAGR)
- -2.49%
- 10 year return (CAGR)
- -
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
PHVS does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 5.54 |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 64.96M |
| EPS (TTM) | -2.63 |
| FCF per share (TTM) | -2.16 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -97.02K |
| Operating income (TTM) | -82.94M |
| Net income (TTM) | -163.72M |
| EPS (TTM) | -2.63 |
| EPS (1y forward) | -2.74 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 329.29M |
| Net receivables | 2.94M |
| Total current assets | 337.19M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 1.61M |
| Total assets | 338.90M |
| Accounts payable | 2.55M |
| Short/Current long term debt | 578.66K |
| Total current liabilities | 26.21M |
| Total liabilities | 26.66M |
| Shareholder's equity | 312.24M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -134.07M |
| Capital expenditures (TTM) | 357.27K |
| Free cash flow (TTM) | -134.43M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -52.43% |
| Return on Assets | -48.31% |
| Return on Invested Capital | -52.41% |
| Cash Return on Invested Capital | -43.03% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 26.49 |
| Daily high | 27.09 |
| Daily low | 25.65 |
| Daily Volume | 57K |
| All-time high | 40.11 |
| 1y analyst estimate | 46.77 |
| Beta | -2.79 |
| EPS (TTM) | -2.63 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 14 Apr 2026 |
Downside potential
Loading...
Downside potential data
| PHVS | S&P500 | |
| Current price drop from All-time high | -33.66% | -1.82% |
| Highest price drop | -95.06% | -56.47% |
| Date of highest drop | 2 Dec 2022 | 9 Mar 2009 |
| Avg drop from high | -54.24% | -10.84% |
| Avg time to new high | 181 days | 12 days |
| Max time to new high | 1250 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.73B
Marketcap category
Small-cap
Description
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Employees
118
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page